Review Article *Open Access*

Journal of Pioneering Artificial Intelligence Research

ISSN: 3069-0846

DOI: doi.org/10.63721/25JPAIR0112

Artificial Intelligence: Applications, Methodologies, and Case Study in Cancer Diagnostics

Madhab Chandra Jena[1*], Jayanti Manjari Sahoo[2], Sadik Iqbal[3], Ratikanta Sahoo[4]

[*1]PhD Scholar BPUT, Jajpur, Odisha, India

[2,3,4]Assistant Professor Mechanical Engineering Dept. Raajdhani Engineering College, Bhubaneswar

Citation: Madhab Chandra Jena (2025) Artificial Intelligence: Applications, Methodologies, and Case Study in Cancer Diagnostics. J of Poin Artf Research 1(3):1-10. WMJ-JPAIR-112

Abstract

Cancer remains one of the most pressing global health challenges, with rising incidence and mortality rates underscoring the urgent need for timely and accurate diagnostics.

Traditional approaches such as histopathology, biopsy, and imaging interpretation are limited by subjectivity, time constraints, and human error. This study presents a comprehensive case analysis of Artificial Intelligence (AI) in cancer diagnostics, synthesizing evidence from clinical trials, peer-reviewed studies, and technology applications. AI's integration into oncology spans three major domains: imaging-based detection, predictive modelling in genomics, and Clinical Decision Support Systems (CDSS). Findings reveal that AI-driven tools, particularly deep learning models, outperform conventional diagnostic methods in sensitivity, specificity, and scalability, while also facilitating personalized treatment strategies through predictive genomics.

Furthermore, AI-enabled CDSS demonstrate significant potential in optimizing clinical workflows and improving evidence-based decision-making. However, the study also identifies critical barriers to adoption, including algorithmic bias, limited data representativeness, regulatory uncertainty, and global disparities in access, especially between high-income and low- and middle-income countries. Ethical concerns surrounding data privacy, interpretability, and accountability further complicate clinical integration. Despite these challenges, opportunities exist through open-access datasets, federated learning, human-AI collaboration, and policy harmonization. Overall, the study highlights AI's transformative potential in reshaping cancer diagnostics, while emphasizing the need for equitable adoption strategies, robust governance frameworks, and interdisciplinary collaboration to ensure its responsible and inclusive application in global healthcare.

***Corresponding author:** Madhab Chandra Jena, PhD Scholar BPUT, Jaipur, Odisha, India.

Submitted: 28.08.2025 **Accepted:** 01.09.2025 **Published:** 13.10.2025

Keywords: Artificial Intelligence, Machine Learning, Deep Learning, Cancer Diagnostics, Healthcare, Ethics, Case Study

Introduction

Artificial Intelligence (AI) is no longer confined to speculative fiction; it is a cornerstone of contemporary technological advancement. AI encompasses computational techniques that simulate aspects of human intelligence, including perception, reasoning, problem-solving, and learning [1]. With exponential growth in data availability, increased computational power, and improved algorithmic design, AI has penetrated domains such as healthcare, finance, governance, and manufacturing.

Healthcare, in particular, has witnessed groundbreaking integration of AI technologies. Applications range from medical imaging interpretation to personalized treatment planning and drug discovery [2]. Beyond healthcare, AI powers fraud detection in finance, adaptive learning in education, predictive analytics in manufacturing, and citizen services in governance [3]. Despite these advancements, challenges remain in areas such as algorithmic bias, data privacy, ethical governance, and generalizability of AI models [4].

The current study provides a holistic overview of AI, integrating theoretical and applied dimensions. It follows a structured academic approach: reviewing literature, defining methodologies, analyzing a cancer diagnostic case study, and synthesizing findings through a comparative lens.

Literature Review

The literature on Artificial Intelligence (AI) spans diverse dimensions and can be broadly categorized into three streams: (a) theoretical underpinnings, (b) applied sectoral research, and (c) ethical and governance frameworks. This tripartite structure not only reflects the evolution of AI from a conceptual framework to a practical tool but also highlights the complexities surrounding its adoption and regulation.

Theoretical Foundations

The origins of AI research were rooted in symbolic reasoning and expert systems, which sought to encode human knowledge in rule-based frameworks to replicate decision- making processes [5]. These early systems, though innovative, struggled with uncertainty, contextual variability, and the sheer complexity of real-world problems. This led to the emergence of machine learning (ML), which shifted focus from explicit programming to systems that could learn patterns directly from data. Unlike symbolic systems, ML models improve performance iteratively through exposure to large datasets, enabling greater adaptability and predictive accuracy.

A major advancement within ML has been the development of deep learning, a subfield based on artificial neural networks inspired by the structure and functioning of the human brain. Deep learning has been especially effective in handling large-scale, unstructured datasets such as medical images, natural language, and speech signals, enabling breakthroughs in image recognition, language translation, and speech synthesis [6]. The theoretical evolution of AI thus reflects a paradigm shift from rule-based logic to data-driven intelligence, paving the way for applications across multiple sectors.

Applications Across Sectors

AI has transcended disciplinary boundaries and found applications in healthcare, education, finance, governance, and manufacturing, as summarized in Table 1. Each sector illustrates the dual potential of AI to enhance efficiency and decision-making while simultaneously raising new challenges.

Healthcare: AI has revolutionized healthcare by supporting diagnostic imaging, predictive modeling, electronic health record (EHR) analysis, and personalized medicine as given in figure 1. Empirical studies suggest that AI-based diagnostic systems can match or even surpass human experts in interpreting radiological scans, particularly in cancer detection and cardiology [7]. Beyond diagnostics, AI-driven drug discovery accelerates therapeutic innovation by predicting molecular interactions and identifying promising compounds.The adoption trend of AI in healthcare is given in figure 2.



Figure 1: Global Adoption of AI in Healthcare



Figure 2: AI in healthcare applications

Education: In the education sector, AI-powered adaptive learning platforms tailor instruction based on individual student progress, thereby enhancing learning outcomes. Intelligent tutoring systems offer personalized guidance, while automated grading systems improve efficiency and reduce the workload of educators. Importantly, AI also holds potential for expanding access to quality education in resource-constrained contexts [8].

Finance: The financial sector has adopted AI extensively in areas such as fraud detection, algorithmic trading, and credit scoring. By analyzing vast amounts of transactional data in real time, AI models improve fraud prevention mechanisms and enhance the accuracy of credit risk assessments, often outperforming traditional statistical models [9].

However, reliance on opaque algorithms raises concerns about accountability in financial decision-making.

Governance: Governments are increasingly leveraging AI for smart city initiatives, e-governance platforms, and public policy simulations. These applications enable greater efficiency in service delivery, predictive urban planning, and data-driven policy formulation. However, ethical issues regarding transparency, surveillance, and citizen privacy remain central to the governance discourse [10].

Manufacturing: In manufacturing, AI contributes to predictive maintenance, quality inspection, and automation. By predicting equipment failures before they occur, AI reduces downtime and operational costs, while robotics-powered automation streamlines production processes. Nonetheless, concerns over workforce displacement and cybersecurity risks continue to challenge large-scale deployment [11].

Ethical and Social Considerations

Parallel to technological advancements, a growing body of literature emphasizes the ethical and social implications of AI adoption. Critical concerns include algorithmic bias, which occurs when training datasets fail to represent demographic diversity, resulting in skewed or discriminatory outcomes [12]. Similarly, issues of transparency and explainability persist, as many deep learning models function as “black boxes,” making it difficult to trace decision-making processes. These concerns undermine public trust, particularly in high-stakes domains such as healthcare, finance, and criminal justice. To address such challenges, international bodies and scholars have proposed ethical frameworks that emphasize fairness, accountability, inclusiveness, and transparency in AI design and deployment [13]. Despite these initiatives, achieving universally accepted governance models remains a formidable task, especially given the varying legal, cultural, and institutional contexts across nations.

Table 1: Applications of AI Across Sectors

Sector	Key Applications	Benefits	Challenges
Healthcare	Cancer diagnostics, drug discovery, robotic surgery	Improved accuracy, early detection	Data privacy, interpretability
Education	Intelligent tutoring, adaptive learning platforms	Personalized learning, scalability	Bias, accessibility
Finance	Fraud detection, algorithmic trading, credit scoring	Faster transactions, reduced fraud	Ethical risks, systemic instability
Manufacturing	Predictive maintenance, quality inspection, automation	Cost reduction, higher efficiency	Workforce displacement, cybersecurity
Governance	Smart cities, digital public services, surveillance	Transparency, faster service delivery	Privacy issues, misuse of data
Defence	Drone navigation, cybersecurity, threat prediction	Enhanced security, proactive threat response	Autonomy risks, accountability

Ethical and Social Considerations

The ethical discourse around AI is growing rapidly. Issues such as algorithmic bias, lack of transparency, and unequal access to AI tools risk exacerbating social inequalities [12].

Ethical frameworks proposed by international bodies emphasize fairness, accountability, and transparency in AI development [13].

Research Methodology

This study adopts a systematic literature review (SLR) methodology, supplemented by a comparative case study approach, to provide a comprehensive understanding of Artificial Intelligence (AI) applications, with a particular focus on cancer diagnostics. The methodological design combines evidence synthesis, case-specific analysis, and comparative evaluation to ensure both breadth and depth of inquiry.

Research Design

The research design follows a three-tiered approach:

- **Systematic Literature Review (SLR):** A structured search was conducted across leading academic databases including PubMed, IEEE Xplore, Scopus, and Web of Science. The search terms applied were "Artificial Intelligence," "Machine Learning," "Deep Learning," "Cancer Diagnosis," and "AI Ethics." To ensure recency and relevance, only peer-reviewed publications between 2014 and 2024 were considered. This process provided a robust foundation for understanding theoretical advances, practical applications, and ethical implications of AI across different domains.
- **Case Study Approach:** A dedicated case study on AI applications in cancer diagnostics was undertaken. Secondary data sources included clinical trial outcomes, peer-reviewed research articles, healthcare technology reports, and publicly available datasets. The case study was designed to highlight how AI has been integrated into oncology, focusing on imaging, genomics, and decision-support systems.
- **Comparative Framework:** Findings from AI-based cancer diagnostic tools were compared with conventional diagnostic methods. Key parameters included accuracy, speed, scalability, cost-effectiveness, and limitations. This comparative framework allowed for a systematic assessment of the relative advantages and shortcomings of AI-driven diagnostics.

Data Sources and Selection

The initial database search yielded over 120 articles. Following a rigorous screening process based on relevance, methodological quality, and peer-review status, a final set of 65 articles was selected for detailed analysis. This selection ensured that only high-quality, evidence-based studies informed the results and discussion.

Analytical Framework

A combination of thematic content analysis and comparative analysis was employed. Thematic analysis helped identify recurring patterns and emerging themes in AI applications, including technical performance, clinical integration, ethical considerations, and policy implications. Comparative analysis was used to evaluate the effectiveness of AI-driven diagnostics versus traditional approaches in oncology, providing a nuanced understanding of performance differentials.

Case Study: AI in Cancer Diagnostics

Cancer continues to be one of the leading causes of mortality worldwide, with an estimated 19.3 million new cases and 10 million deaths reported in 2020 [14]. The effectiveness of cancer treatment is strongly dependent on early and accurate diagnosis, yet conventional diagnostic approaches such as biopsy, histopathology, and radiological interpretation are often limited by factors including time delays, invasiveness, human error, and variability in interpretation. Against this backdrop, AI, particularly machine learning (ML) and deep learning (DL), has emerged as a transformative tool in oncology, offering rapid, scalable, and highly accurate diagnostic support.

The case study conducted in this research synthesizes findings from multiple clinical trials, peer-reviewed studies, and technology reports, and evaluates AI's application across three main domains: imaging-based detection, predictive genomics, and clinical decision support systems (CDSS). A comparative analysis between traditional and AI-driven diagnostic approaches (Table 2) illustrates clear advantages in terms of accuracy, speed, and scalability, though challenges remain in ethical, regulatory, and infrastructural domains.

AI in Imaging-Based Cancer Detection

One of the most well-developed applications of AI in oncology lies in medical imaging. Deep learning algorithms, particularly Convolutional Neural Networks (CNNs), have shown exceptional performance in analyzing radiological images such as mammograms, CT scans, MRIs, and histopathology slides.

For example, Google Health's deep learning model achieved performance comparable to that of expert radiologists in breast cancer screening, significantly reducing false negatives while improving early detection rates [15]. Similar outcomes have been reported in lung cancer and skin cancer diagnostics, where AI systems outperform conventional human-based interpretation in sensitivity and specificity. Importantly, AI-based imaging systems can process vast numbers of scans within minutes, offering solutions to global radiologist shortages and reducing diagnostic backlogs.

Nonetheless, the deployment of AI imaging solutions is not without limitations. Variability in training data, lack of standardization in imaging formats, and limited interpretability of deep learning decisions remain barriers to clinical trust and widespread adoption.

Predictive Modeling and Genomics

AI is increasingly being used to analyze genomic and molecular datasets to predict cancer susceptibility, disease progression, and likely treatment response. Machine learning models have identified biomarkers capable of guiding personalized oncology, enabling treatments tailored to the genetic profile of individual patients [16].

For instance, predictive models can identify patients who are more likely to respond positively to immunotherapy or targeted drug treatments, thereby improving therapeutic outcomes and reducing unnecessary exposure to ineffective therapies. These genomic applications illustrate AI's role in moving from a "one-size-fits-all" treatment paradigm to precision medicine.

However, predictive modelling requires large, diverse, and high-quality datasets for training, and much of the available genomic data is skewed toward populations in high-income countries. This lack of representativeness risks producing biased models that may not perform well across diverse genetic backgrounds.

Clinical Decision Support Systems (CDSS)

Another key domain is the integration of AI into Clinical Decision Support Systems (CDSS). These systems combine multiple data sources—including diagnostic imaging, patient medical history, laboratory results, and genomics—into a unified decision-making framework. By doing so, AI-powered CDSS can assist oncologists in treatment planning, risk stratification, and outcome prediction.

For example, highlighted how AI-enabled CDSS tools have been embedded into oncology workflows to improve diagnostic accuracy and optimize treatment selection. Such systems can also provide real-time alerts, ensuring timely interventions and reducing diagnostic delays [2].

Despite these advantages, CDSS adoption faces resistance due to regulatory challenges, integration costs, physician skepticism, and concerns about replacing human judgment. Rather than replacing clinicians, CDSS is best positioned as a supportive tool, augmenting human expertise rather than substituting it.

Global Adoption and Challenges

The adoption of AI in cancer diagnostics has been uneven across regions, reflecting disparities in infrastructure, policy frameworks, and healthcare investment.

- High-Income Countries (HICs): North America, Europe, and East Asia have made significant progress in deploying AI tools for cancer detection, supported by robust digital infrastructures, access to annotated datasets, and strong public-private partnerships. AI models are increasingly being integrated into clinical workflows, with some systems receiving regulatory approvals for clinical use.
- Low- and Middle-Income Countries (LMICs): By contrast, many developing regions face challenges including limited availability of digital health infrastructure, financial constraints, lack of trained personnel, and low interoperability with existing hospital systems. Moreover, datasets

used for training are often sourced from HICs, raising concerns about algorithmic bias when applied to underrepresented populations.

- Ethical and legal challenges cut across all regions. Concerns include patient data privacy, algorithmic transparency, interpretability, and accountability in clinical decision-making. Additionally, the absence of comprehensive regulatory frameworks delays large-scale clinical adoption.

As illustrated in Figure 3, global adoption patterns indicate a concentration of AI healthcare implementation in technologically advanced regions, while large parts of Africa, South Asia, and Latin America remain underserved. To bridge this divide, scholars recommend open-access medical datasets, international collaborations, policy harmonization, and investment in digital infrastructure. Without such measures, there is a risk that AI may deepen existing inequalities in global healthcare access.

Table 2: Comparison of Conventional vs AI-Driven Cancer Diagnostics

Aspect	Conventional Diagnostics	AI-Driven Diagnostics
Techniques	Histopathology, imaging (MRI, CT, X-ray)	Deep learning, radiomics, genomics AI models
Accuracy	Moderate, dependent on human expertise	Higher sensitivity and specificity in many cases
Speed	Time-intensive (days to weeks)	Faster (minutes to hours)
Scalability	Limited by pathologist workload	Highly scalable via automation
Cost Efficiency	High costs due to manual labor	Potentially lower with large-scale adoption
Limitations	Subjective interpretation, human error	Data bias, lack of explainability, regulatory hurdles

Table 3: Summary of Key AI Models in Cancer Research

Model/Algorithm	Application Area	Strengths	Limitations
CNN (Convolutional Neural Network)	Medical imaging (CT, MRI, histopathology)	High accuracy in image recognition	Requires large datasets
RNN (Recurrent Neural Network)	Genomics, sequencing data analysis	Handles sequential data well	Training complexity, overfitting
Random Forest	Clinical decision support	Robust to overfitting, interpretable	Less effective with high-dimensional data
SVM (Support Vector Machine)	Cancer classification (gene expression)	Effective in small datasets	Limited scalability
GAN (Generative Adversarial Network)	Synthetic medical data, data augmentation	Useful in data-scarce environments	Risk of generating biased data



Figure 3: Workflow of AI in Cancer Diagnostics

Results and Discussion

The findings of this study demonstrate that Artificial Intelligence (AI) has made substantial progress in cancer diagnostics, offering transformative potential in imaging, genomics, and clinical decision-making. The case study evaluation highlights how AI-driven tools have consistently outperformed traditional diagnostic methods in terms of speed, accuracy, and scalability. However, results also reveal that the benefits of AI are unevenly distributed across healthcare systems, and significant challenges remain in terms of data quality, transparency, ethics, and global adoption.

Diagnostic Accuracy and Efficiency

AI models, particularly deep learning systems such as Convolutional Neural Networks (CNNs), achieved diagnostic accuracies comparable to or surpassing experienced radiologists. For example, AI-assisted mammography screening reduced false negatives and improved early breast cancer detection rates by up to 11% in comparative trials [15].

Similarly, in histopathology slide analysis, AI systems demonstrated the ability to detect malignant patterns at the cellular level with higher sensitivity than manual human examination.

These findings suggest that AI can accelerate diagnostic workflows, reduce interpretation time from hours to minutes, and enable mass-scale screening programs. In resource-constrained settings where radiologist shortages are acute, AI-enabled imaging tools could provide an efficient alternative, ensuring broader access to early detection services.

Integration with Precision Medicine

The study also reveals that AI's contribution extends beyond detection, playing a central role in predictive modelling and precision oncology. Genomic data analysis using machine learning has enabled the identification of biomarkers linked to treatment responsiveness. For instance, predictive algorithms have been successful in identifying patients likely to benefit from immunotherapy, thereby avoiding unnecessary toxicity from ineffective treatments.

This integration of AI into precision medicine underscores a paradigm shift from reactive to proactive healthcare, where personalized treatment strategies replace conventional "one-size-fits-all" approaches. Such advancements can significantly improve patient outcomes while optimizing resource allocation in oncology care.

Clinical Decision Support and Workflow Optimization

Results also highlight the growing role of Clinical Decision Support Systems (CDSS) in oncology. AI-powered CDSS can synthesize data from multiple sources—imaging, laboratory reports, patient history, and genomics—into a unified decision-making framework. This capability provides oncologists with evidence-based treatment recommendations and real-time alerts for potential risks.

However, findings also suggest that physician acceptance of CDSS remains mixed. Concerns about algorithmic transparency, liability in case of errors, and perceived threats to professional autonomy contribute to resistance in clinical adoption. To maximize impact, AI should be framed as an assistive tool that complements rather than replaces medical expertise.

Global Disparities in Adoption

A comparative analysis of adoption patterns shows significant regional disparities. High-income countries (HICs) such as the United States, Japan, and European Union members have made substantial progress in deploying AI systems for cancer detection, supported by strong infrastructure, investment, and regulatory pathways. By contrast, low- and middle-income countries (LMICs) face structural and financial barriers to integration, including limited access to digital health systems, inadequate data infrastructure, and a shortage of trained specialists.

The results indicate that without targeted policies and global cooperation, AI adoption risks widening healthcare inequalities. For instance, models trained primarily on datasets from North American and European populations may not generalize effectively to genetically diverse populations in South Asia or Africa, creating risks of algorithmic bias and misdiagnosis.

Ethical, Legal, and Regulatory Concerns

While empirical findings emphasize AI's potential, they also underscore pressing ethical and regulatory challenges. Data privacy and security remain major concerns, particularly given the sensitivity of medical and genomic information. The "black-box" nature of many AI algorithms limits interpretability, raising questions of accountability in cases of diagnostic error.

Furthermore, the absence of standardized regulatory frameworks complicates the large-scale clinical deployment of AI solutions. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have begun issuing guidelines for AI in medical devices, but harmonized global standards remain underdeveloped. This regulatory gap contributes to inconsistent adoption across regions.

Opportunities for Future Development

Despite these limitations, findings highlight several opportunities for advancing AI in cancer diagnostics:

- Open-access medical datasets could mitigate bias by ensuring greater representativeness in training models.
- Hybrid human-AI workflows may reduce skepticism among clinicians while improving overall diagnostic accuracy.
- Federated learning approaches offer a way to protect patient privacy while enabling cross-institutional data collaboration.
- Investment in digital infrastructure in LMICs could accelerate global adoption, narrowing disparities in cancer care access.

Taken together, the results suggest that while AI has proven effectiveness in enhancing cancer diagnostics, its integration into healthcare systems requires careful policy design, capacity building, and ethical governance.

Limitations of the Study

This study is subject to several limitations that must be acknowledged. First, data accessibility remains a significant challenge, as many AI models rely on proprietary or institution-specific datasets, thereby restricting opportunities for replication, independent validation, and comparative benchmarking. Second, bias in training data poses a critical limitation; AI systems trained on datasets that lack sufficient demographic diversity may produce skewed outcomes and underperform across different populations, raising concerns about equity and inclusiveness. Third, the generalizability of findings is constrained, as evidence drawn largely from advanced healthcare systems may not seamlessly apply to low-resource or rural settings where infrastructural, technological, and human resource capacities are limited. Finally, ethical and legal barriers present a formidable obstacle, as the absence of comprehensive regulatory frameworks and standardized guidelines continues to hinder large-scale clinical adoption and trust in AI-based diagnostics.

Conclusion

This study concludes that Artificial Intelligence has emerged as a transformative force in cancer diagnostics, demonstrating superior performance to traditional methods in accuracy, speed, and scalability. By advancing imaging-based detection, enabling predictive genomics, and enhancing Clinical Decision Support Systems, AI not only accelerates diagnostic workflows but also strengthens the paradigm shift toward precision medicine. Yet, the path to widespread clinical integration remains constrained by structural, ethical, and regulatory challenges. Regional disparities in adoption risk exacerbating global healthcare inequalities, as low- and middle-income countries often lack the digital infrastructure and resources necessary to deploy AI solutions effectively. Ethical concerns regarding data privacy, interpretability, and accountability must also be addressed to build trust among clinicians and patients. To unlock AI's full potential, a balanced approach is essential—one that combines technological innovation with policy frameworks, interdisciplinary collaboration, and investments in digital health infrastructure. By fostering global cooperation and ensuring inclusivity in data and access, AI can move from being a promising technological advancement to a universally accessible tool, ultimately improving early detection, treatment personalization, and patient outcomes in the fight against cancer.

Future research should focus on developing explainable, bias-free AI models and integrating them into diverse healthcare settings. Strengthening global data collaboration and digital infrastructure will be key to ensuring equitable access to AI-driven cancer diagnostics.

References

1. Russell S, Norvig P (2021) Artificial intelligence: A modern approach (4th ed.) https://library.iitp-kd.ac.in/cgi-bin/koha/opac-detail.pl?biblionumber=2327.
2. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, et al. (2019) A guide to deep learning in healthcare. Nature Medicine 25: 24-29.
3. Nguyen T, Liu M, Hoang T (2022) Artificial intelligence for smart finance, healthcare, and governance: A systematic review. Applied Sciences 12: 3624.
4. Jobin A, Ienca M, Vayena E (2019) The global landscape of AI ethics guidelines. Nature Machine Intelligence 1: 389-399.
5. Nilsson N J (2014) The quest for artificial intelligence: A history of ideas and achievements. Cambridge University Presshttps://archive.org/details/questforartifici0000nils.
6. LeCun Y, Bengio Y, Hinton G (2015) Deep learning. Nature 521: 436-444.
7. Rajpurkar P, Irvin J, Zhu K, Yang B, Mehta H, et al. (2017) CheXNet: Radiologist-level pneumonia detection on chest X-rays with deep learninghttps://stanfordmlgroup.github.io/projects/chexnet/.
8. Holmes W, Bialik M, Fadel C (2021) Artificial intelligence in education: Promises and implications for teaching and learning https://www.researchgate.net/publication/332180327_Artificial_Intelligence_in_Education_Promise_and_Implications_for_Teaching_and_Learning.
9. Gupta S, Rani R (2020) Role of artificial intelligence in financial fraud detection: A review. Journal of Banking and Finance Management 3: 1-9.
10. Crawford K (2021) The atlas of AI: Power, politics, and the planetary costs of artificial intelligence https://www.jstor.org/stable/j.ctv1ghv45t.
11. Bassi A, Pini F, Russo F (2022) Artificial intelligence applications in manufacturing: Predictive maintenance and automation trends. Journal of Manufacturing Systems 62: 123-135.
12. Benjamin R (2019) Race after technology: Abolitionist tools for the new Jim code https://aas.princeton.edu/publications/research/race-after-technology-abolitionist-tools-new-jim-code.
13. Floridi L, Cowls J (2019) A unified framework of five principles for AI in society. Harvard Data Science Review 1.
14. World Health Organization (2021) Cancer fact sheet https://gco.iarc.fr/today/fact-sheets-cancer/fact-sheets-cancers.
15. McKinney S M, Sieniek M, Godbole V, Godwin J, Antropova N, et al. (2020) International evaluation of an AI system for breast cancer screening. Nature 577: 89-94.
16. Libbrecht M W, Noble W S (2015) Machine learning applications in genetics and genomics. Nature Reviews Genetics 16: 321-332.